Company Directory

AAV gene therapy platform targeting podocyte-mediated kidney disease

Purespring Therapeutics is a clinical-stage biotech developing AAV-based gene therapies for chronic kidney disease. Its platform delivers therapeutic transgenes directly to podocytes, specialised cells implicated in the majority of renal diseases, enabling disease-modifying treatment of both rare monogenic and more prevalent acquired kidney conditions. The lead programme, PS-002, targets IgA nephropathy and has received MHRA CTA approval for a Phase I/II trial.

Blood-based liquid biopsy for endothelial glycocalyx and microvascular health

Dimension Biotechnologies is a biotech developing a rapid, blood-based diagnostic for microvascular health based on analysis of the endothelial glycocalyx, the molecular layer lining blood vessel walls whose biochemical integrity is disrupted early in cardiovascular disease, kidney disease, diabetes, and sepsis. The platform detects glycocalyx biomarker signatures from a blood sample using spectroscopic methods compatible with existing laboratory equipment, enabling non-invasive assessment of microvascular health for clinical prognostics and drug development research.

AI-driven drug discovery targeting necrosis and age-related disease

LinkGevity is a preclinical-stage biotechnology company developing anti-necrotic therapeutics for age-related and degenerative diseases. Founded in 2023 and based at Babraham Research Campus, the company's proprietary Blueprint Theory of Ageing identifies necrosis as a key driver of biological decline, informing its AI-enabled drug discovery platform. Its lead programme targets kidney disease, with broader applications across age-related conditions.

FDA-approved AI blood test for diabetic kidney disease risk

Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on the clinical management of chronic kidney disease. Its blood-based test combines biomarker analysis with machine learning to generate a five-year kidney function decline risk score in adults with type 2 diabetes and CKD stages 1 to 3b. Renalytix serves healthcare providers across the United States and has partnered with Tempus AI to expand access through integrated electronic health record systems.

Specialist renal pharmaceuticals and clinical nutrition products

Stanningley Pharma is a specialty pharmaceutical company focused on products for patients with chronic kidney disease and other hospital medicine therapeutic areas. The company licenses, develops, and markets prescription medicines and Foods for Special Medical Purposes into the NHS, including a calcium acetate phosphate binder, renal nutritional supplements, and haem iron products for iron deficiency. It actively partners with multinational companies to support product development and commercialisation.

AI-driven precision therapeutics for metabolic syndrome diseases

Multiomic Health is a data-centric therapeutics company developing precision medicines for metabolic syndrome-related conditions, including type 2 diabetes, cardiovascular disease, chronic kidney disease and non-alcoholic fatty liver disease. The company integrates multi-omics data with longitudinal clinical datasets and applies AI-enabled computational systems biology modelling to identify disease endotypes and patient subpopulations, informing both therapeutic development and companion diagnostics.

Small molecule therapeutics targeting PDE4 enzymes in kidney disease

Mironid is a company developing first-in-class small molecule therapeutics for autosomal dominant polycystic kidney disease, one of the most common hereditary kidney disorders. Its lead programme targets long-form PDE4 enzymes to modulate cyclic AMP signalling, the central driver of cyst growth across all disease stages. Spun out of the University of Strathclyde and Heriot-Watt University in 2014, the company has raised £35 million to date and is progressing its lead molecule through IND-enabling studies.

DUB inhibitor therapeutics targeting mitophagy and degenerative disease

Mission Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule inhibitors of deubiquitylating enzymes to treat diseases driven by mitochondrial dysfunction. By targeting a mitochondria-localised DUB, the company's drug candidates are designed to enhance mitophagy, the cellular process that removes damaged mitochondria, promoting cell and organ health. Its clinical pipeline addresses Parkinson's disease, acute kidney injury, and Duchenne muscular dystrophy, with candidates currently in Phase I and Phase II trials.

Engineered macrophage cell therapy for inflammatory and fibrotic disease

Resolution Therapeutics is a clinical-stage biotech developing regenerative macrophage therapies for inflammatory and fibrotic diseases. Its platform harnesses the tissue-repairing properties of macrophages, engineering them to deliver anti-fibrotic and anti-inflammatory effects at sites of organ damage. The lead programme, RTX001, is an autologous engineered macrophage therapy in a Phase I/II trial for end-stage liver disease. The pipeline extends into graft-versus-host disease and lung fibrosis. The company has raised £73.5 million, backed by Syncona.

Independent global health research institute focused on chronic diseases

The George Institute for Global Health (UK) is an independent medical research institute conducting large-scale clinical trials, population studies, and health policy research on non-communicable diseases. Based at Imperial College London's White City Campus and affiliated with Imperial as a strategic partner, the UK programme addresses cardiovascular disease, chronic kidney disease, stroke, women's health, diabetes, food policy, and planetary health. The institute operates as a WHO Collaborating Centre for Injury Prevention and Trauma Care.